Morgan Stanley Assigns Equal Weight Rating to ABIVAX Société Anonyme

On March 23rd, 2025, Morgan Stanley reaffirmed its "equal weight" rating on the shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research note released to investors. The investment firm has set a target price of $12.00 for the stock.

In addition to Morgan Stanley, several other analysts have provided their insights on ABIVAX Société Anonyme. For instance, JMP Securities recently maintained a "market outperform" rating with a price target of $33.00 in a report dated January 10th. Furthermore, Citizens JMP upgraded ABIVAX to a "strong buy" rating on December 4th.

Overall, the stock has received varied ratings from analysts: one research analyst issued a hold rating, while five have provided buy ratings, and one has assigned a strong buy rating to the stock. According to data gathered by MarketBeat.com, ABIVAX currently holds a consensus rating of "Buy" with an average price target of $38.00.

ABIVAX Stock Performance

As of Thursday, ABIVAX shares opened at $7.38, reflecting a 4.5% increase. The stock’s 50-day moving average price stands at $6.73, while its 200-day moving average price is $8.52. Over the past twelve months, the stock has ranged from a low of $5.50 to a high of $16.63.

Institutional Investment Activity

Recent activity among institutional investors has seen notable changes in their stakes in ABIVAX. For instance, Two Sigma Investments LP acquired a new stake valued at $144,000 in the fourth quarter. Similarly, Stonepine Capital Management LLC has a stake worth $110,000, and Shay Capital LLC invested $366,000 in ABIVAX during the same period.

Millennium Management LLC increased its stake in ABIVAX by 44.2%, now owning 931,179 shares valued at $6,816,000 after acquiring an additional 285,542 shares. Furthermore, Citadel Advisors LLC boosted its stake by an impressive 83.5% in the fourth quarter, now holding 855,676 shares valued at $6,264,000. Collectively, institutional investors and hedge funds own approximately 47.91% of ABIVAX's stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme operates as a clinical-stage biotechnology company, dedicated to developing therapies that leverage the body’s natural regulatory mechanisms to stabilize immune responses in patients coping with chronic inflammatory diseases. The company is currently advancing its lead drug candidate, obefazimod, which is undergoing Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

ABIVAX, Stocks, MorganStanley